Domů › Autoimunitní onemocnění › Texas › Houston
Klinické studie Autoimunitní onemocnění v Houston, TX
21 studií pro Autoimunitní onemocnění hledá účastníky v lokalitách v Houston a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Probíhá náborFáze 2
- MD Anderson Cancer Center, Houston
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Probíhá náborFáze 3
- Abigail Neiman MD PA, Houston
- Novel Research LLC, Bellaire · Vzdálenost 7 mi
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Probíhá náborFáze 2
- Jade Clinical Site, Houston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Probíhá náborFáze 1
- UT MD Anderson Cancer Center, Houston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Probíhá náborFáze 3
- Baylor College of Medicine, Houston
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Probíhá náborFáze 2/3
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Probíhá náborFáze 2
- University of Texas - Houston, Houston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Probíhá náborFáze 3
- Baylor College of Medicine, Houston
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Probíhá náborFáze 3
- GSK Investigational Site, Houston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Probíhá náborFáze 1/2
- University of Texas MD Anderson Cancer Center, Houston
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Probíhá náborFáze 3
- Nephro Asso North Illinois Indiana, Houston
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Probíhá náborFáze 1/2
- Baylor College of Medicine Neurology Department, Houston
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Probíhá náborFáze 3
- Texas Children's Hospital/ Baylor College of Medicine, Houston
Study of BHV-1300 in Graves' Disease
Probíhá náborFáze 1
- Site-106, Houston
- Site-101, Houston
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Probíhá náborFáze 3
- Site Number - 1057, Houston
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Probíhá náborFáze 2/3
- Houston Methodist Hospital, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Probíhá náborObservační studie
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Probíhá náborFáze 1/2
- MD Anderson Texas Medical Center, Houston
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Probíhá náborObservační studie
- M D Anderson Cancer Center, Houston
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Probíhá náborFáze 1/2
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Probíhá náborFáze 1
- Houston Methodist Hospital, Houston
Studie Autoimunitní onemocnění v jiných městech
- Washington, DC19 studií
- New York City, NY19 studií
- Philadelphia, PA16 studií
- Durham, NC15 studií
- Boston, MA13 studií
- Los Angeles, CA12 studií
- Chicago, IL12 studií
- Dallas, TX9 studií
- Cleveland, OH8 studií
- Milwaukee, WI8 studií
- Atlanta, GA8 studií
- Portland, OR8 studií
Další studie v Houston
- Nemalobuněčný plicní karcinom145 studií
- Rakovina prsu126 studií
- Rakovina (všechny typy)121 studií
- Metastatický karcinom104 studií
- Kolorektální karcinom102 studií
- Rakovina vaječníků89 studií
- Akutní myeloidní leukemie85 studií
- Rakovina plic78 studií
- Rakovina prostaty76 studií
- Rakovina endometria68 studií
- Rakovina slinivky břišní61 studií
- Melanom59 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.